Home > Media Room > Press Release

Media Room

Press Release
Media Kit

Press Release

2012

Ipca Laboratories Q1 FY13 Results (June 30, 2012)

Ipca Laboratories Q1 FY13 Results

Net Total Income at Rs. 637.38 crores, up by 20%
Export Income at Rs. 366.73 crores, up by 24%
EBITDA at Rs. 141.78 crores, up by 50%
EBITDA margin @ 22.35% as against 17.79% in Q1FY12
Net Profit at Rs. 42.98 crores, down by 30%
(on account of forex translations/transactions loss of Rs. 58.85 crores)

Mumbai, India, July 31, 2012: Ipca Laboratories Limited today announced its unaudited financial results for the first quarter ended 30^th June, 2012 of the financial year 2012-13.

Key Highlights of Q1 FY13

Net Total Income at Rs. 637.38 crores in Q1 FY13 as against Rs. 532.55 crores in Q1 FY12, growth of 20%.
Export Income at Rs. 366.73 crores in Q1 FY13 as against Rs. 296.66 crores in Q1 FY12, growth of 24%.
EBITDA at Rs. 141.78 crores in Q1 FY13 as against Rs. 94.26 crores in Q1 FY12, up by 50%.
EBITDA margin increased from 17.79% to 22.35%.
Net Profit at Rs. 42.98 crores in Q1 FY13 as against Rs. 61.67 crores in Q1 FY12, down by 30% on account of forex transactions / translations loss of Rs. 58.85 crores in the quarter as against forex transactions / translations gain of Rs. 9.10 crores in the corresponding quarter of the previous financial year.

Revenue Break-up

Formulations:

Total Revenue from formulations business at Rs. 448.69 crores in Q1 FY13 as against Rs. 395.55 crores in Q1 FY12, growth of 13%.
Revenue from Domestic branded formulations business at Rs. 224.18 crores in Q1 FY13 as against Rs. 188.97 crores in Q1 FY12, growth of 19%.
Revenue from export of formulations at Rs. 224.51 crores in Q1 FY13 as against Rs. 206.58 crores in Q1 FY12, growth of 9%.

Active Pharmaceutical Ingredients (APIs)

Total Revenues from Active Pharmaceutical Ingredients (APls) business at Rs. 181.56 crores in Q1 FY13 as against Rs. 130.78 crores in Q1 FY12, growth of 39%.
Revenues from Domestic Active Pharmaceutical Ingredients (APls) business at Rs. 39.34 crores in Q1 FY13 as against Rs. 40.70 crores in Q1 FY12, down by 3%.
Revenue from export of Active Pharmaceutical Ingredients (APls) at Rs. 142.22 crores in Q1 FY13 as against Rs. 90.08 crores in Q1 FY12, growth of 58%.

Q1 FY13 at a glance

(Rs. Crores)

1^st Quarter ended	30.6.2012	30.6.2011	Growth
Net Total Income	637.38	532.55	20%
Export Income	366.73	296.66	24%
EBITDA	141.78	94.26	50%
Profit before Forex gain / loss and tax	115.33	74.09	56%
Forex (gain) / loss	58.85	(9.10)	-
Net Profit after Forex gain / loss and tax	42.98	61.67	(30%)
Earnings per share of Rs. 2/- each (Rs)	3.41	4.91	(30%)

About Ipca Laboratories:

Ipca Laboratories is a fast growing pharmaceutical major, with a strong thrust on exports. Exports to over 110 countries, now account for nearly 55% of Company's income. Ipca Laboratories is vertically integrated and produces finished dosage forms and Active Pharmaceutical Ingredients.

Premchand Godha
Chairman & Managing Director

Encl: Audited Financial Results

Contact Information:

Harish P. Kamath, Sr. V.P. Legal & Company Secretary at harish.kamath@ipca.com or on +91-22-66474644

Ipca Laboratories FY 2011-12 Audited Results (May 29, 2012)

Ipca FY 2011-12 Audited Resultst

Net Total Income at Rs. 2342.29 crores, up by 24%
EBITDA at Rs. 513.48 crores, up by 37%
Net Profit at Rs. 280.17 crores, up by 10%
EBITDA margin @ 22.04% in FY12 as against 19.97% in FY11
Final Dividend of Re. 1.20 per share (60%) recommended

Mumbai, India, May 29, 2012: Ipca Laboratories Limited today announced its audited financial results for the financial year ended 31^st March, 2012.

Key Highlights of FY12:

Net Total Income at Rs. 2342.29 crores in FY12 as against Rs. 1889.61 crores in FY11, growth of 24%.
Export Income at Rs. 1401.97 crores in FY12 as against Rs. 1025.18 crores in FY11, growth of 37%.
EBITDA at Rs. 513.48 crores in FY12 as against Rs. 375.73 crores in FY11, growth of 37%.
EBITDA margin @ 22.04% in FY12 as against 19.97% in FY11.
Net Profit at Rs. 280.17 crores in FY12 as against Rs. 255.37 crores in FY11, growth of 10%.
Earnings per share of Rs. 2/- each at Rs. 22.23 in FY12 as against Rs. 20.36 in FY11.

Revenue Break-up - FY12

Formulations:

Revenue from Indian formulations business at Rs. 753.41 crores in FY12 as against RS. 695.66 crores in FY11, growth of 8%.
Revenue from export formulations business at Rs. 996.14 crores in FY12 as against Rs. 691.71 crores in FY11, growth of 44%.
Total Revenue from formulations business at Rs. 1749.55 crores in FY12 as against Rs. 1387.37 crores in FY11, growth of 26%.
Formulations business now constitute 76% of the Company's net sales.

Active Pharmaceutical Ingredients (APIs)

Revenues from Indian Active Pharmaceutical Ingredients (APls) business at Rs. 143.86 crores in FY12 as against
Rs. 145.08 crores in FY11, de-growth of 1%.
Revenue from export Active Pharmaceutical Ingredients (APls) business at Rs. 405.83 crores in FY12 as against
Rs. 333.47 crores in FY11, growth of 22%.
Total Revenues from Active Pharmaceutical Ingredients (APls) business at Rs. 549.69 crores in FY12 as against
Rs. 478.55 crores in FY11, growth of 15%.

FY 2011-12 at a glance

(Rs. Crores)

Year ended	31.3.2012	31.3.2011	Growth
Net Total Income	2242.29	1889.61	24%
Export Income	1401.97	1025.18	37%
EBITDA	513.48	375.73	37%
Profit before Forex gain, Tax and provision for investment in subsidiaries	421.73	300.36	40%
Forex (gain) / loss	52.79	(43.34)	-
Provision for investment in subsidiaries	-	9.96	-
Net Profit	280.17	255.37	10%
Earnings per share of Rs. 2/- each (Rs.)	22.23	20.36	9%

About Ipca Laboratories:

Ipca Laboratories is a fast growing pharmaceutical major, with a strong thrust on exports. Exports to over 110 countries, now account for 60% of Company's income. Ipca Laboratories is vertically integrated and produces finished dosage forms and Active Pharmaceutical Ingredients.

Premchand Godha
Chairman & Managing Director

Encl: Audited Financial Results

Contact Information:

Harish P. Kamath, Sr. V.P. Legal & Company Secretary at harish.kamath@ipca.com or on +91-22-66474644

Q4 FY12 Financial Results (May 29, 2012)

Q4 FY12 Financial Results

Net Total Income at Rs. 564.83 crores, up by 18%
EBITDA at Rs. 111.67 crores, up by 14%
Net Profit at Rs. 76.61 crores, up by 31%
EBITDA margin @ 19.90% in Q4 FY12 as against 20.43% in Q4 in FY11

Q4 2011-12 at a glance

(Rs. Crores)

4^th Quarter ended	31.3.2012	31.3.2011	Growth
Net Total Income	564.83	479.68	18%
Export Income	371.16	309.67	20%
EBITDA	111.67	97.73	14%
Profit before Forex gain, Tax and provision for investment in subsidiaries	90.04	75.88	19%
Forex gain	5.14	6.22	-
Provision for investment in subsidiaries	-	9.96	-
Net Profit	76.61	58.57	31%
Earnings per share of Rs. 2/- each (Rs.)	6.08	4.67	30%

In view of the amalgamation of Tonira Pharma Ltd. with the Company effective 1^st April, 2011, the financial figures for the current quarter / year are not strictly comparable with that of previous quarter / year.

About Ipca Laboratories:

Premchand Godha
Chairman & Managing Director

Encl: Audited Financial Results

Contact Information:

Harish P. Kamath, Sr. V.P. Legal & Company Secretary at harish.kamath@ipca.com or on +91-22-66474644

2011

Ipca Laboratories FY 2010-11 Audited Results (May 24, 2011)

Ipca FY 2010-11 Audited Resultst

Net Total Income at Rs. 1889.54 crores, up by 21%
EBITDA at Rs. 378.49 crores, up by 14%
Net Profit at Rs. 255.37 crores, up by 22%
Final Dividend of Re. 1.20 per share (60%) recommended

Mumbai, India, May 24, 2011: Ipca Laboratories Limited today announced its audited financial results for the financial year ended 31^st March, 2011.

Key Highlights of FY11:

Net Total Income at Rs. 1889.54 crores in FY11 as against Rs. 1565.50 crores in FY10, growth of 21%.
Export Income at Rs. 1025.18 crores in FY11 as against Rs. 806.08 crores in FY10, growth of 27%.
EBITDA at Rs. 378.49 crores in FY11 as against Rs. 331.89 crores in FY10, growth of 14%.
EBITDA margin @ 20.12% in FY11 as against 21.37% in FY10.
Net Profit at Rs. 255.37 crores in FY11 as against Rs. 209.19 crores in FY10, growth of 22%.
Earnings per share of Rs. 2 /- each at Rs. 20.36 in FY11 as against Rs. 16.75 in FY10.

Revenue Break-up - FY11

Formulations:

Revenue from Indian formulations business at Rs. 696.41 crores in FY11 as against RS. 597.84 crores in FY10, growth of 16%.
Revenue from export formulations business at Rs. 691.71 crores in FY11 as against Rs. 489.15 crores in FY10, growth of 41%.
Total Revenue from formulations business at Rs. 1388.12 crores in FY11 as against Rs. 1086.99 crores in FY10, growth of 28%.
Formulations business now constitute 74% of the Company's net sales.

Active Pharmaceutical Ingredients (APIs)

Revenues from Indian Active Pharmaceutical Ingredients (APls) business at Rs. 144.33 crores in FY11 as against Rs. 141.63 crores in FY10, growth of 2%.
Revenue from export Active Pharmaceutical Ingredients (APls) business at Rs. 333.47 crores in FY11 as against Rs. 316.93 crores in FY10, growth of 5%.
Total Revenues from Active Pharmaceutical Ingredients (APls) business at Rs. 477.80 crores in FY11 as against Rs. 458.56 crores in FY10, growth of 4%.

FY 2010-11 at a glance

(Rs. Crores)

Year ended	31.3.2011	31.3.2010	Growth
Net Total Income	1889.54	1565.50	21%
Export Income	1025.18	806.08	27%
EBITDA	378.49	331.89	14%
Profit before Forex gain, Tax and provision for investment in subsidiaries	300.36	265.94	13%
Forex gain	43.34	5.79	-
Provision for investment in subsidiaries	9.96	-	-
Net Profit	255.37	209.19	22%
Earnings per share of Rs. 2/- each (Rs.)	20.36	16.75	22%

About Ipca

Ipca is a fast growing pharmaceutical major, with a strong thrust on exports. Exports to over 110 countries, now account for 54% of Company's income. Ipca is vertically integrated and produces finished dosage forms and Active Pharmaceutical Ingredients.

Premchand Godha
Chairman & Managing Director

Encl: Audited Financial Results

Contact Information:

Harish P. Kamath, Sr. V.P. Legal & Company Secretary at harish.kamath@ipca.com or on +91-22-66474644

Q4 FY11 Financial Results (May 24, 2011)

Q4 FY11 Financial Results

Net Total Income at Rs. 485.23 crores, up by 29%
EBITDA at Rs. 98.27 crores, up by 45%
Net Profit at Rs. 58.57 crores, up by 57%
EBITDA margin @ 20.54% in Q4 FY 11 as against 18.38% in Q4 in FY10

Q4 2010-11 at a glance

(Rs. Crores)

4^th Quarter ended	31.3.2011	31.3.2010	Growth
Net Total Income	485.23	375.05	29%
Export Income	309.67	210.13	47%
EBITDA	98.27	67.60	45%
Profit before Forex gain, Tax and provision for investment in subsidiaries	75.88	50.70	50%
Forex gain	6.22	1.83	-
Provision for investment in subsidiaries	9.96	-	-
Net Profit	58.57	37.29	57%
Earnings per share of Rs. 2/- each (Rs.)	4.67	2.99	57%

About Ipca

Premchand Godha
Chairman & Managing Director

Encl: Audited Financial Results

Contact Information:

Harish P. Kamath, Sr. V.P. Legal & Company Secretary at harish.kamath@ipca.com or on +91-22-66474644

Ipca's SEZ Indore formulation manufacturing unit gets UK-MHRA approval (March 9, 2011)

Ipca's SEZ Indore formulation manufacturing unit gets UK-MHRA approval.

Ipca Laboratories Ltd. formulation manufacturing unit situated at Pharma zone, SEZ Indore, Pithampur, Madhya Pradesh has been inspected and certified that it complies with the principles and guidelines of Good Manufacturing Practices laid down in the directives by the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.

It is the fourth manufacturing unit of the company to have received such approval from MHRA, U.K.

Ipca Q3 FY11 Results (January 25, 2011)

Ipca Q2 FY11 Results

Net Total Income at Rs. 466.71 crores, up by 18%
Net Profit at Rs. 63.95 crores, up by 10%
2^nd Interim Dividend of Re.1/- per share (50%) declared

Mumbai, India, January 25, 2011: Ipca today announced its unaudited financial results for the 3^rd quarter ended 31^st December, 2010 of the financial year 2010-11.

Key Highlights of Q3 FY11:

Net Total Income at Rs. 466.71 crores in Q3 FY11 as against Rs. 396.61 crores in Q3 FY10, growth of 18%.
Export Income at Rs. 253.66 crores in Q3 FY11 as against Rs. 201.21 crores in Q3 FY10, growth of 26%.
EBITDA at Rs. 90.99 crores in Q3 FY11 as against Rs. 90.31 crores in Q3 FY10.
EBITDA margin @19.51% in Q3 FY11 as against 22.82% in Q3 FY10.
Net Profit at Rs. 63.95 crores in Q3 FY11 as against Rs. 58.25 crores in Q3 FY10, growth of 10%.
EPS of Rs. 5.10 in Q3 FY11 as against Rs. 4.66 in Q3 FY10.
2^nd Interim Dividend of Re.1/- per share (50%) declared making the total interim dividend declared to Rs. 2/- per share (100%) for the FY 2010-11.

Revenue Break-up - Q3 FY11

Formulations:

Revenue from Indian formulations business at Rs. 177.50 crores in Q3 FY11 as against Rs. 158.92 crores in Q3 FY10, growth of 12%.
Revenue from export formulations business at Rs. 167.13 crores in Q3 FY11 as against Rs. 125.74 crores in Q3 FY10, growth of 33%.
Total Revenue from formulations business at Rs. 344.63 crores in Q3 FY11 as against Rs. 284.66 crores in Q3 FY10, growth of 21%.

Active Pharmaceutical Ingredients (APIs)

Revenue from Indian Active Pharmaceutical Ingredients (APIs) business at Rs. 32.19 crores in Q3 FY11 as against Rs. 33.75 crores in Q3 FY10, de-growth of 5%.
Revenue from export Active Pharmaceutical Ingredients (APIs) business at Rs. 86.53 crores in Q3 FY11 as against Rs. 75.47 crores in Q3 FY10, growth of 15%.
Total Revenue from Active Pharmaceutical Ingredients (APIs) business at Rs. 118.72 crores in Q3 FY11 as against Rs. 109.22 crores in Q3 FY10, growth of 9%.

Key Highlights of 9 Months FY11:

Net Total Income at Rs. 1404.31 crores in 9 months FY11 as against Rs. 1190.45 crores in 9 months FY10, growth of 18%.
Export Income at Rs. 715.51 crores in 9 months FY11 as against Rs. 595.95 crores in 9 months FY10, growth of 20%.
EBITDA at Rs. 280.22 crores in 9 months FY11 as against Rs. 264.29 crores in 9 months FY10, growth of 6%.
EBITDA margin @ 19.98% in 9 months FY11 as against 22.30% in 9 months FY10.
Net Profit at Rs. 196.80 crores in 9 months FY11 as against Rs. 171.90 crores in 9 months FY10, growth of 14%.
EPS of Rs. 15.69 in 9 months FY11 as against Rs. 13.75 in 9 months FY10

Revenue Break-up - 9 months FY11

Formulations:

Revenue from Indian formulations business at Rs. 567.64 crores in 9 months FY11 as against Rs. 475.30 crores in 9 months FY10, growth of 19%.
Revenue from export formulations business at Rs. 464.26 crores in 9 months FY11 as against Rs. 358.04 crores in 9 months FY10, growth of 30%.
Total Revenue from forumlations business at Rs. 1031.90 crores in 9 months FY11 as against Rs. 833.34 crores in 9 months FY10, growth of 24%.
Formulations business now constitutes 74% of the Company's net sales.

Active Pharmaceutical Ingredients (APIs)

Revenue from Indian Active Pharmaceutical Ingredients (APIs) business at Rs. 108.99 crores in 9 months FY11 as against Rs. 109.18 crores in 9 months FY10.
Revenue from export Indian Active Pharmaceutical Ingredients (APIs) business at Rs. 251.25 crores in 9 months FY11 as against Rs. 237.91 crores in 9 months FY10, growth of 6%.
Total Revenue from Active Pharmaceutical Ingredients (APIs) business at Rs. 360.24 crores in 9 months FY11 as against Rs. 347.09 crores in 9 months FY10, growth of 4%.

Q3 FY11 at a glance

(Rs. Crores)

3^rd Quarter ended	331.12.2010	31.12.2009	Growth
Net Total Income	466.71	396.61	18%
Export Income	253.66	201.21	26%
EBITDA	90.99	90.31	1%
Profit before Forex gain/(loss) and tax	71.54	74.00	(3)%
Forex gain/ (loss)	11.21	(1.65)	-
Net Profit after Forex gain/(loss) and tax	63.95	58.25	10%
Earnings per share of Rs. 2/- each (Rs.)	5.10	4.66	10%

9 Months FY11 at a glance

(Rs. Crores)

9 Months' ended	31.12.2010	31.12.2009	Growth
Net Total Income	1404.31	1190.45	18%
Export Income	715.51	595.95	20%
EBITDA	280.22	264.29	6%
Profit before Forex gain/(loss) and tax	224.48	215.24	4%
Forex gain/(loss)	37.12	3.96	-
Net Profit after Forex gain/(loss) and tax	196.80	171.90	14%
Earnings per share of of Rs. 2/- each (Rs.)	15.69	13.75	14%

About Ipca

Ipca is a fast growing pharmaceutical major, with a strong thrust on exports. Exports to over 110 countries, now account for nearly half of Company's income. Ipca is vertically integrated and produces finished dosage forms and Active Pharmaceutical Ingredients.

Premchand Godha
Chairman & Managing Director

Encl: Unaudited Financial Results

Contact Information:

Harish P. Kamath, Sr. V.P. Legal & Company Secretary at harish.kamath@ipca.com or on +91-22-66474644

2010

Ipca Q2 FY11 Results (October 22, 2010)

Ipca Q2 FY11 Results

Net Total Income at Rs. 519.04 crores, up by 20%
EBITDA at Rs. 118.00 crores, up by 16%
Net Profit at Rs. 94.01 crores, up by 47%
Interim Dividend of Re.1/- per share (50%) declared

Mumbai, India, October 22, 2010: Ipca today announced its unaudited financial results for the second quarter ended 30^th September, 2010 of the financial year 2010-11.

Key Highlights of Q2 FY11:

Net Total Income at Rs. 519.04 crores in Q2 FY11 as against Rs. 430.79 crores in Q2 FY10, growth of 20%.
Export Income at Rs. 251.53 crores in Q2 FY11 as against Rs. 219.54 crores in Q2 FY10, growth of 15%.
EBITDA at Rs. 118.00 crores in Q2 FY11 as against Rs. 102.12 crores in Q2 FY10, growth of 16%.
EBITDA margin @19.51% in Q3 FY11 as against 22.82% in Q3 FY10.
EBITDA margin @22.77% in Q2 FY11 as against 23.73% in Q2 FY10.
Net Profit at Rs. 94.01 crores in Q2 FY11 as against Rs. 63.88 crores in Q2 FY10, growth of 47%.
EPS of Rs. 7.49 in Q2 FY11 as against Rs. 5.10 in Q2 FY10.
Interim Dividend of Re.1/- per share (50%) declared.

Revenue Break-up - Q2 FY11

Formulations:

Total Revenue from formulations business at Rs. 397.04 crores in Q2 FY11 as against Rs. 309.24 crores in Q2 FY10, growth of 28%.
Revenue from Indian formulations business at Rs. 221.94 crores in Q2 FY11 as against Rs. 171.49 crores in Q2 FY10, growth of 29%.
Revenue from export formulations business at Rs. 175.10 crores in Q2 FY11 as against Rs. 137.75 crores in Q1 FY10, growth of 27%.

Active Pharmaceutical Ingredients (APIs)

Total Revenues from Active Pharmaceutical Ingredients (APIs) business at Rs. 117.26 crores in Q2 FY11 as against Rs. 119.55 crores in Q2 FY10, growth of -2%.
Revenues from Indian Active Pharmaceutical Ingredients (APIs) business at Rs. 40.83 crores in Q2 FY11 as against Rs. 37.76 crores in Q2 FY10, growth of 8%.
Revenue from export of Active Pharmaceutical Ingredients (APIs) business at Rs. 76.43 crores in Q2 FY11 as against Rs. 81.79 crores in Q2 FY10, growth of -7%

Key Highlights of H1 FY11:

Net Total Income of Rs. 937.60 crores in H1 FY11 as against Rs. 793.84 crores in H1 FY10, growth of 18%.
Export Income at Rs. 461.85 crores in H1 FY11 as against Rs. 394.74 crores in H1 FY10, growth of 17%.
EBITDA at Rs. 189.23 in H1 FY11 as against Rs. 173.98 crores in H1 FY10, growth of 9%.
EBITDA margin @ 20.21% in H1 FY11 as against 22.05% in H1 FY10.
Net Profit at Rs. 132.85 crores in H1 FY11 as against Rs. 113.65 crores in H1 FY10, growth of 17%.
EPS of Rs. 10.59 in H1 FY11 as against Rs. 9.08 in H1 FY10.

Revenue Break-up - H1 FY11

Formulations:

Total Revenue from formulations business at Rs. 687.27 crores in H1 FY11 as against Rs. 548.69 crores in H1 FY10, growth of 25%.
Revenue from Indian formulations business at Rs. 390.14 crores in H1 FY11 as against Rs. 316.39 crores in H1 FY10, growth of 23%.
Revenue from export of forumlations business at Rs. 297.13 crores in H1 FY11 as against Rs. 232.30 crores in H1 FY10, growth of 28%.

Active Pharmaceutical Ingredients (APIs)

Total Revenues from Active Pharmaceutical Ingredients (APIs) business at Rs. 241.52 crores in H1 FY11 as against Rs. 237.87 crores in H1 FY10, growth of 2%.
Revenues from Indian Active Pharmaceutical Ingredients (APIs) business at Rs. 76.80 crores in H1 FY11 as against Rs. 75.43 crores in H1 FY10, growth of 2%.
Revenue from export Active Pharmaceutical Ingredients (APIs) business at Rs. 164.72 crores in H1 FY11 as against Rs. 162.44 crores in H1 FY10, growth of 1%.
Till date, the Company has filed 20 ANDAs with US-FDA out of which 10 ANDAs are granted.
54 DMFs are also filed with US-FDA for Active Pharmaceutical Ingredients (APIs).

Q2 FY11 at a glance

(Rs. Crores)

2^nd Quarter ended	30.09.2010	30.09.2009	Growth
Net Total Income	519.04	430.79	20%
Export Income	251.53	219.54	15%
EBITDA	118.00	102.12	16%
Profit before Forex gain/(loss) and tax	98.87	83.89	18%
Forex gain/ (loss)	28.84	(0.56)	-
Net Profit after Forex gain/(loss) and tax	94.01	63.88	47%
Earnings per share of Rs. 2/- each (Rs.)	7.49	5.10	47%

H1 FY11 at a glance

(Rs. Crores)

Half Year ended	30.09.2010	30.09.2009	Growth
Net Total Income	937.60	793.84	18%
Export Income	461.85	394.74	17%
EBITDA	189.23	173.98	9%
Profit before Forex gain/(loss) and tax	152.94	141.24	8%
Forex gain/(loss)	25.91	35.61	-
Net Profit after Forex gain/(loss) and tax	132.85	113.65	17%
Earnings per share of of Rs. 2/- each (Rs.)	10.59	9.08	17%

About Ipca

Premchand Godha
Chairman & Managing Director

Encl: Unaudited Financial Results

Contact Information:

Harish P. Kamath, V.P. Legal & Company Secretary at harish.kamath@ipca.com or on +91-22-66474644

Ipca Q1 FY11 Results (July 29, 2010)

Ipca Q1 FY11 Results

Net Total Income at Rs. 418.56 crores, up by 15%
Export Income at Rs. 210.32 crores, up by 20%
EBITDA at Rs. 71.23 crores, down by 1%
Net Profit at Rs. 38.84 crores, down by 22%

Mumbai, India, July 29, 2010: Ipca today announced its unaudited financial results for the first quarter ended 30^th June, 2010 of the financial year 2010-11.

Key Highlights of Q1 FY11:

Net Total Income at Rs. 418.56 crores in Q1 FY11 as against Rs. 363.05 crores in Q1 FY10, growth of 15%.
Export Income at Rs. 210.32 crores in Q1 FY11 as against Rs. 175.20 crores in Q1 FY10, growth of 20%.
EBITDA at Rs. 71.23 crores in Q1 FY11 as against Rs. 71.86 crores in Q1 FY10, down by 1%.
EBITDA margin reduced from 20% to 17%.
Net Profit at Rs. 38.84 crores in Q1 FY11 as against Rs. 49.77 crores in Q1 FY10, reduced by 22%.
EPS of Rs. 3.10 in Q1 FY11 as against Rs. 3.99 in Q1 FY10.
The sales and profitability of Q1 FY11 was impacted mainly on account of.

- The sales and profitability of Q1 FY11 was impacted mainly on account of:
- Appreciation of Indian Rupee against major currencies vis-a-vis Q1 FY10; and
- Aggressive expansion of domestic field force and resultant increase in employees cost and marketing expenses.

Revenue Break

Formulations:

Total Revenue from formulations business at Rs. 290.23 crores in Q1 FY11 as against Rs. 239.53 crores in Q1 FY10, growth of 21%.
Revenue from export formulations business at Rs. 137.75 crores in Q2 FY10 as against Rs. 105.84 crores in Q1 FY09, growth of 30%.
Total Revenue from formulations business at Rs. 309.24 crores in Q2 FY10 as against Rs. 255.95 crores in Q2 FY09, growth of 21%.

Active Pharmaceutical Ingredients (APIs)

Revenues from Indian Active Pharmaceutical Ingredients (APIs) business at Rs. 37.76 crores in Q2 FY10 as against Rs. 29.28 crores in Q2 FY09, growth of 29%.
Revenue from Domestic branded formulations business at Rs. 168.20 crores in Q1 FY11 as against Rs. 144.90 crores in Q1 FY10, growth of 16%.
Revenue from export of formulations at Rs. 122.03 crores in Q1 FY11 as against Rs. 94.63 crores in Q1 FY10, growth of 29%.

Active Pharmaceutical Ingredients (APIs)

Total Revenues from Active Pharmaceutical Ingredients (APIs) business at Rs. 124.26 crores in Q1 FY11 as against Rs. 118.24 crores in Q1 FY10, growth of 5%.
Revenues from Domestic Active Pharmaceutical Ingredients (APIs) business at Rs. 35.97 crores in Q1 FY11 as against Rs. 37.67 crores in Q1 FY10, down by 5%.
Revenue from export of Active Pharmaceutical Ingredients (APIs) business at Rs. 88.29 crores in Q1 FY11 as against Rs. 80.57 crores in Q1 FY10, growth of 10%.
EDecline in anti-malarial API sales in the domestic and export markets impacted the API sales growth.

Q1 FY11 at a glance

(Rs. Crores)

1^stQuarter ended	30.06.2010	30.06.2009	Growth
Net Total Income	418.56	363.05	15%
Export Income	210.32	175.20	20%
EBITDA	71.23	71.86	(1%)
Profit before Forex gain/(loss) and tax	54.08	57.35	(6%)
Forex gain/ (loss)	(2.93)	(6.17)	-
Net Profit after Forex gain/(loss) and tax	38.84	49.77	(22%)
Earnings per share of Rs. 10/- each (Rs.)	3.10	3.99	(22%)

About Ipca

Premchand Godha
Chairman & Managing Director

Encl: Unaudited Financial Results

Contact Information:

Harish P. Kamath, V.P. Legal & Company Secretary at harish.kamath@ipca.com or on +91-22-66474644

Ipca FY 2009-10 Audited Results (June 3, 2010)

Ipca FY 2009-10 Audited Results

Net Total Income at Rs. 1558.95 crores, up by 22%
EBITDA at Rs. 331.89 crores, up by 24%
Net Profit at Rs. 209.19 crores, up by 129%
Final Dividend of Re. 1/- per share (50%) recommended

Mumbai, India, May 28, 2010: Ipca today announced its audited financial results for the financial year ended 31^st March, 2010.

Key Highlights of FY10:

Net Total Income at Rs. 1558.95 crores in FY10 as against Rs. 1275.57 crores in FY09, growth of 22%.
Export Income at Rs. 806.08 crores in FY10 as against Rs. 680.39 crores in FY09, growth of 18%.
EBITDA at Rs. 331.89 crores in FY10 as against Rs. 267.80 crores in FY09, growth of 24%.
EBITDA margin @ 21.37% in FY10 as against 21.03% in FY09.
Net Profit at Rs. 209.19 crores in FY10 as against Rs. 91.22 crores in FY09, growth of 129%.
Earnings per share of Rs. 2/- each at Rs. 16.75 in FY10 as against Rs. 7.27 in FY09.

Revenue Break-up - FY10

Formulations:

Revenue from Indian formulations business at Rs. 597.84 crores in FY10 as against Rs. 476.59 crores in FY09, growth of 25%.
Revenue from export formulations business at Rs. 489.15 crores in FY10 as against Rs. 437.17 crores in FY09, growth of 12%.
Total Revenue from formulations business at Rs. 1086.99 crores in FY10 as against Rs. 913.76 crores in FY09, growth of 19%.
Formulations business now constitute 70% of the Company's net sales.

Active Pharmaceutical Ingredients (APIs)

Revenues from Indian Active Pharmaceutical Ingredients (APIs) business at Rs. 141.63 crores in FY10 as against Rs. 108.34 crores in FY09, growth of 31%.
Revenue from export Active Pharmaceutical Ingredients (APIs) business at Rs. 316.93 crores in FY10 as against Rs. 243.22 crores in FY09, growth of 30%.
Total Revenues from Active Pharmaceutical Ingredients (APIs) business at Rs. 458.56 crores in FY10 as against Rs. 351.56 crores in FY09, growth of 30%.

FY10 at a glance

(Rs. Crores)

Year ended	31.03.2010	31.03.2009	Growth
Net Total Income	1558.95	1275.57	22%
Export Income	806.08	680.39	18%
EBITDA	331.89	267.80	24%
Profit before Forex gain/(loss) and tax	265.94	200.34	33%
Forex gain/ (loss)	5.79	(75.69)	-
Net Profit after Forex gain/(loss) and tax	209.19	91.22	129%
Earnings per share of Rs. 2/- each (Rs.)	16.75	7.27	130%

About Ipca

Premchand Godha
Chairman & Managing Director

Encl: Unaudited Financial Results.

Contact Information:

Harish P. Kamath, V.P. Legal & Company Secretary at harish.kamath@ipca.com or on +91-22-66474644

Q3 FY10 Results (January 21, 2010)

Q3 FY10 Results

Net Total Income at Rs. 396.61 crores, up by 26%
EBITDA at Rs. 90.31 crores, up by 27%
Net Profit at Rs. 58.25 crores, up by 151%
2^nd Interim Dividend of Rs. 4/- per share (40%) declared
Stock split of 5 equity shares of Rs. 2/- each for every 1 equity share of Rs .10/- each announced.

Mumbai, India, January 21, 2010: Ipca today announced its unaudited financial results for the 3^rd quarter ended 31^st December, 2009 of the financial year 2009-10.

Key Highlights of Q3 FY10:

Net Total Income at Rs .396.61 crores in Q3 FY10 as against Rs. 313.63 crores in Q3 FY09, growth of 26%.
Export Income at Rs. 201.21 crores in Q3 FY10 as against Rs. 169.97 crores in Q3 FY09, growth of 18%.
EBITDA at Rs. 90.31 crores in Q3 FY10 as against Rs. 71.22 crores in Q3 FY09, growth of 27%.
EBITDA margin @ 22.82% in Q3 FY10 as against 22.73% in Q3 FY09.
Net Profit at Rs. 58.25 crores in Q3 FY10 as against Rs. 23.18 crores in Q3 FY09, growth of 151%.
EPS of Rs. 23.30 in Q3 FY10 as against Rs. 9.21 in Q3 FY09.
2^nd Interim Dividend of Rs. 4/- per share (40%) declared making the total interim dividend declared to Rs. 9/- per share (90%) for the FY 2009-10.
Stock split of 5 equity shares of Rs. 2/- each for every 1 equity share of Rs. 10/- each announced.

Revenue Break-up - Q3 FY10

Formulations:

Revenue from Indian formulations business at Rs. 158.92 crores in Q3 FY10 as against Rs. 115.57 crores in Q3 FY09, growth of 38%.
Revenue from export formulations business at Rs. 125.74 crores in Q3 FY10 as against Rs. 113.59 crores in Q1 FY09, growth of 11%.
Total Revenue from formulations business at Rs. 309.24 crores in Q2 FY10 as against Rs. 255.95 crores in Q2 FY09, growth of 21%.

Active Pharmaceutical Ingredients (APIs)

Revenues from Indian Active Pharmaceutical Ingredients (APIs) business at Rs.33.79 crores in Q3 FY10 as against Rs. 25.57 crores in Q3 FY09, growth of 32%.
Revenue from export Active Pharmaceutical Ingredients (APIs) business at Rs.75.47 crores in Q3 FY10 as against Rs. 56.38 crores in Q3 FY09, growth of 34%.
Total Revenues from Active Pharmaceutical Ingredients (APIs) business at Rs.109.26 crores in Q3 FY10 as against Rs. 81.95 crores in Q3 FY09, growth of 33%.

Key Highlights of 9 Months FY10

Net Total Income at Rs. 1190.45 crores in 9 months FY10 as against Rs. 956.98 crores in 9 months FY09, growth of 24%.
Export Income at Rs. 595.95 crores in 9 months FY10 as against Rs. 488.30 crores in 9 months FY09, growth of 22%.
EBITDA at Rs. 264.29 crores in 9 months FY10 as against Rs. 213.99 crores in 9 months FY09, growth of 24%.
EBITDA margin @22.30% in 9 months FY10 as against 22.39% in 9 months FY09.
Net Profit at Rs. 171.90 crores in 9 months FY10 as against Rs. 83.32 crores in 9 months FY09, growth of 106%.
EPS of Rs. 68.77 in 9 months FY10 as against Rs. 33.10 in 9 months FY09.

Revenue Break-up - H1 FY10

Formulations:

Revenue from Indian formulations business at Rs. 316.39 crores in H1 FY10 as against Rs. 266.51 crores in H1 FY09, growth of 19%.
Revenue from export formulations business at Rs. 232.30 crores in H1 FY10 as against Rs. 194.41 crores in H1 FY09, growth of 19%.
Total Revenue from formulations business at Rs. 548.69 crores in H1 FY10 as against Rs. 460.92 crores in H1 FY09, growth of 19%.

Revenue Break-up - 9months FY10

Formulations:

Revenue from Indian formulations business at Rs. 475.30 crores in 9 months FY10 as against Rs. 382.07 crores in 9 months FY09, growth of 24%.
Revenue from export Active Pharmaceutical Ingredients (APIs) business at Rs. 237.91 crores in 9 months FY10 as against Rs. 180.30 crores in 9 months FY09, growth of 32%.
Total Revenue from formulations business at Rs. 833.34 crores in 9 months FY10 as against Rs. 690.07 crores in 9 months FY09, growth of 21%.
Formulations business now constitute 70% of the Company's net sales.

Active Pharmaceutical Ingredients (APIs)

Revenues from Indian Active Pharmaceutical Ingredients (APIs) business at Rs. 109.22 crores in 9 months FY10 as against Rs. 78.69 crores in 9 months FY09, growth of 39%.
Revenue from export formulations business at Rs. 358.04 crores in 9 months FY10 as against Rs. 308.00 crores in 9 months FY09, growth of 16%.
Total Revenues from Active Pharmaceutical Ingredients (APIs) business at Rs. 347.13 crores in 9 months FY10 as against Rs. 258.99 crores in 9 months FY09, growth of 34%.

Q3 FY10 at a glance

(Rs. Crores)

3^rd Quarter ended	31.12.2009	31.12.2008	Growth
Net Total Income	396.61	313.63	26%
Export Income	201.21	169.97	18%
EBITDA	90.31	71.22	27%
Profit before Forex gain/(loss) and tax	74.00	49.72	49%
Forex gain/ (loss)	(1.65)	(19.23)	-
Net Profit after Forex gain/(loss) and tax	58.25	23.18	151%
Earnings per share of Rs. 10/- each (Rs.)	23.30	9.21	153%

9 Months FY10 at a glance

(Rs. Crores)

9 Months ended	31.12.2009	31.12.2008	Growth
Net Total Income	1190.45	956.98	24%
Export Income	595.95	488.30	22%
EBITDA	264.29	213.99	24%
Profit before Forex gain/(loss) and tax	215.24	164.00	31%
Forex gain/(loss)	3.96	(60.33)	-
Net Profit after Forex gain/(loss) and tax	171.90	83.32	106%
Earnings per share of Rs.10/- each (Rs.)	68.77	33.10	108%

About Ipca

Premchand Godha
Chairman & Managing Director

Encl: Unaudited Financial Results.

Contact Information:

Harish P. Kamath, V.P. Legal & Company Secretary at harish.kamath@ipca.com or on +91-22-66474644

2009

Q2 Financials Results ( (November 02, 2009)

Q2 FY10 Results

Net Total Income at Rs. 430.79 crores, up by 24%
EBITDA at Rs. 102.12 crores, up to 23%
Net Profit at Rs. 63.88 crores, up by 75%
2^nd Interim Dividend of Rs. 4/- per share (40%) declared
Interim Dividend of Rs. 5/- per share (50%) declared

Mumbai, India, October 27, 2009: Ipca today announced its unaudited financial results for the second quarter ended 30^th September, 2009 of the financial year 2009-10.

Key Highlights of Q2 FY10

Net Total Income at Rs. 430.79 crores in Q2 FY10 as against Rs. 348.05 crores in Q2 FY09, growth of 24%.
Export Income at Rs. 219.54 crores in Q2 FY10 as against Rs. 165.81 crores in Q2 FY09, growth of 32%.
EBITDA at Rs. 102.12 crores in Q2 FY10 as against Rs. 83.23 crores in Q2 FY09, growth of 23%.
EBITDA margin @ 23.73% in Q2 FY10 as against 23.95% in Q2 FY09.
Net Profit at Rs. 63.88 crores in Q2 FY10 as against Rs. 36.51 crores in Q2 FY09 growth of 75%.
EPS of Rs. 25.52 in Q2 FY10 as against Rs. 14.49 in Q2 FY09.
Interim Dividend of Rs. 5/- per share (50%) declared.

Revenue Break-up - Q2 FY10

Formulations:

Revenue from Indian formulations business at Rs. 171.49 crores in Q2 FY10 as against Rs. 150.11 crores in Q2 FY09, growth of 14%.
Revenue from export formulations business at Rs. 137.75 crores in Q2 FY10 as against Rs. 105.84 crores in Q1 FY09, growth of 30%.
Total Revenue from formulations business at Rs. 309.24 crores in Q2 FY10 as against Rs. 255.95 crores in Q2 FY09, growth of 21%.

Active Pharmaceutical Ingredients (APIs)

Revenues from Indian Active Pharmaceutical Ingredients (APIs) business at Rs. 37.76 crores in Q2 FY10 as against Rs.29.28 crores in Q2 FY09, growth of 29%.
Revenue from export Active Pharmaceutical Ingredients (APIs) business at Rs. 81.79 crores in Q2 FY10 as against Rs.59.97 crores in Q2 FY09, growth of 36%.
Total Revenues from Active Pharmaceutical Ingredients (APIs) business at Rs. 119.55 crores in Q2 FY10 as against Rs.89.25 crores in Q2 FY09, growth of 34%.

Key Highlights of H1 FY10

Net Total Income at Rs. 793.84 crores in H1 FY10 as against Rs. 643.35 crores in H1 FY09, growth of 23%.
Export Income at Rs. 394.74 crores in H1 FY10 as against Rs. 318.33 crores in H1 FY09, growth of 24%.
EBITDA at Rs. 173.98 crores in H1 FY10 as against Rs. 142.77 crores in H1 FY09, growth of 22%.
EBITDA margin @22.05% in H1 FY10 as against 22.22% in H1 FY09.
Net Profit at Rs. 113.65 crores in H1 FY10 as against Rs. 60.14 crores in H1 FY09, growth of 89%.
EPS of Rs. 45.39 in H1 FY10 as against Rs. 23.87 in H1 FY09.

Revenue Break-up - H1 FY10

Formulations

Revenue from Indian formulations business at Rs. 316.39 crores in H1 FY10 as against Rs. 266.51 crores in H1 FY09, growth of 19%.
Revenue from export formulations business at Rs. 232.30 crores in H1 FY10 as against Rs. 194.41 crores in H1 FY09, growth of 19%.
Total Revenue from formulations business at Rs. 548.69 crores in H1 FY10 as against Rs. 460.92 crores in H1 FY09, growth of 19%.

Active Pharmaceutical Ingredients (APIs)

Revenues from Indian Active Pharmaceutical Ingredients (APIs) business at Rs. 75.43 crores in H1 FY10 as against Rs. 53.12 crores in H1 FY09, growth of 42%.
Revenue from export Active Pharmaceutical Ingredients (APIs) business at Rs. 162.44 crores in H1 FY10 as against Rs. 123.92 crores in H1 FY09, growth of 31%.
Total Revenues from Active Pharmaceutical Ingredients (APIs) business at Rs. 237.87 crores in H1 FY10 as against Rs. 177.04 crores in H1 FY09, growth of 34%.
Till date, the Company has filed 14 ANDAs with US-FDA out of which 9 ANDAs are granted.
49 DMFs are also filed with US-FDA for Active Pharmaceutical Ingredients (APIs).

Q2 FY10 at a glance

(Rs. Crores)

2^nd Quarter ended	30.09.2009	30.09.2008	Growth
Net Total Income	430.79	348.05	24%
Export Income	219.54	165.81	32%
EBITDA	102.12	83.23	23%
Profit before Forex gain/(loss) and tax	83.89	67.32	25%
Forex gain/ (loss)	(0.56)	(19.23)	-
Net Profit after Forex gain/(loss) and tax	63.88	36.51	75%
Earnings per share of Rs. 10/- each (Rs.)	25.52	14.49	76%

H1 FY10 at a glance

(Rs. Crores)

Half Year ended	30.09.2009	30.09.2008	Growth
Net Total Income	793.84	643.35	23%
Export Income	394.74	318.33	24%
EBITDA	173.98	142.77	22%
Profit before Forex gain/(loss) and tax	141.24	114.28	24%
Forex gain/(loss)	5.61	(41.10)	-
Net Profit after Forex gain/(loss) and tax	113.65	60.14	89%
Earnings per share of of Rs. 10/- each (Rs.)	45.39	23.87	90%

About Ipca

Ajit K. Jain
Executive Director

Encl: Audited Financial Results

Contact Information:

Harish P. Kamath, V.P. Legal & Company Secretary at harish.kamath@ipca.com or on +91-22-66474644

Press Release - FY10 Results (June 30, 2009)

Ipca Q1 FY10 Results

Net Total Income at Rs. 363.05 crores, up by 23%
EBITDA at Rs. 71.86 crores, up to 21%
Net Profit at Rs. 49.77 crores, up by 111%

Mumbai, India, July 30, 2009: Ipca today announced its unaudited financial results for the first quarter ended 30^th June, 2009 of the financial year 2009-10.

Key Highlights of Q1 FY10

Net Total Income at Rs. 363.05 crores in Q1 FY10 as against Rs. 295.30 crores in Q1 FY09, growth of 23%.
Export Income at Rs. 175.20 crores in Q1 FY10 as against Rs. 152.52 crores in Q1 FY09, growth of 15%.
EBITDA at Rs. 71.86 crores in Q1 FY10 as against Rs. 59.54 crores in Q1 FY09, growth of 21%.
EBITDA margin unchanged @20% for the quarter.
Net Profit at Rs. 49.77 crores in Q1 FY10 as against Rs. 23.63 crores in Q1 FY09, growth of 111%.
EPS of Rs. 19.86 in Q1 FY10 as against Rs. 9.38 in Q1 FY09.

Revenue Break-up

Formulations:

Revenue from Indian branded formulations business at Rs. 144.90 crores in Q1 FY10 as against Rs. 116.39 crores in Q1 FY09, growth of 24%.
Revenue from export of formulations at Rs. 94.63 crores in Q1 FY10 as against Rs. 89.00 crores in Q1 FY09, growth of 6%.
Total Revenue from formulations business at Rs. 239.53 crores in Q1 FY10 as against Rs. 205.39 crores in Q1 FY09, growth of 17%.

Active Pharmaceutical Ingredients (APIs)

Revenues from Indian Active Pharmaceutical Ingredients (APIs) business at Rs. 37.67 crores in Q1 FY10 as against Rs. 23.85 crores in Q1 FY09, growth of 58%.
Revenue from export of Active Pharmaceutical Ingredients (APIs) at Rs. 80.57 crores in Q1 FY10 as against Rs. 63.52 crores in Q1 FY09, growth of 27%.
Total Revenues from Active Pharmaceutical Ingredients (APIs) business at Rs. 118.24 crores in Q1 FY10 as against Rs. 87.37 crores in Q1 FY09, growth of 35%.
Till date, the Company has filed 13 ANDAs with US-FDA out of which 9 ANDAs are granted.
46 DMFs are also filed with US-FDA for Active Pharmaceutical Ingredients (APIs).

Q1 FY10 at a glance

(Rs. Crores)

1^st Quarter ended	30.06.2009	30.06.2008	Growth
Net Total Income	363.05	295.30	23%
Export Income	175.20	152.52	15%
EBITDA	71.86	59.54	21%
Profit before Forex gain/(loss) and tax	57.35	46.96	22%
Forex gain/ (loss)	6.17	(17.51)	-
Net Profit after Forex gain/(loss) and tax	49.77	23.63	111%
Earnings per share of Rs. 10/- each (Rs.)	19.86	9.38	112%

About Ipca

Premchand Godha
Chairman & Managing Director

Encl: Unaudited Financial Results

Contact Information:

Ajit K. Jain, Executive Director at ajit@ipca.co.in or on +91-22-66474654

Harish P. Kamath, V.P. Legal & Company Secretary at harish.kamath@ipca.com or on +91-22-66474644

Financial Results (May 28, 2009)

Highlights

Financial year 2008-09 total income up 20% to Rs. 1275.57 crores.
EBIDT before forex translations loss/gain up 45% to Rs. 270 crores.
Net Profit, after foreign exchange translations loss of Rs. 75.69 crores (previous year gain of Rs. 42.72 crores) and provision for exceptional item, is Rs. 91.22 crores (Previous year - Rs. 141.12 crores).
Final dividend of Rs. 4/- per share recommended. Total dividend for financial year Rs. 11/- per share (previous year Rs. 8/- per share).
11 ANDA applications of formulations developed by the Company filed with US FDA, 9 of which are granted. Exports of generic formulations to US commenced.

Financial Results

Ipca has posted improved financial results for the year ended 31^st March, 2009. The total income for the year has gone up by 20% to Rs. 1275.57 crores as against Rs. 1059.16 crores in the previous year. Export Sales for the year increased by 27% to Rs. 680.39 crores.

Though, Earnings before foreign exchange translations loss / gain, provision for investment / loan in a wholly owned subsidiary and tax has increased by 49% to Rs. 200.34 crores, after providing for Rs.75.69 crores towards foreign exchange translations loss (previous year - gain of Rs. 42.72 crores), exceptional item and taxes, the net profit for the year is down by 35% at Rs. 91.22 crores.

The Board has recommended a final dividend of Rs. 4/- per share for the financial year 2008-09. Together with interim dividends of Rs. 7/- per share already declared and paid, the total dividend for the financial year amounts to Rs. 11/- per share as against Rs. 8/- per share in the previous year.

4^th Quarter at a glance

(Rs. Crores)

4^th Quarter ended	31.03.2009	31.03.2008	Growth
Net Total Income	318.59	251.18	27%
Export Income	192.92	147.35	31%
Profit before forex loss/gain, exceptional item and tax	36.34	24.92	46%
Forex Translations loss	(15.36)	(0.18)	-
Provision for investment/ loan in a wholly owned subsidiary	(10.19)	-	-
Net Profit after forex loss/gain, exceptional item and tax	7.90	22.64	(65)%
Diluted Earnings per share (Rs.)	3.14	9.02	(65)%

2008-09 Audited Results at a glance

(Rs. Crores)

Year ended	31.03.2009	31.03.2008	Growth
Net Total Income	1275.57	1059.16	20%
Export Income	680.39	536.26	27%
Profit before forex loss/ gain, exceptional item and tax	200.34	134.15	49%
Forex Translations loss	(75.69)	42.72	-
Provision for investment/ loan in a wholly owned subsidiary)	(10.19)	-	-
Net Profit after forex loss/gain, exceptional item and tax	91.22	141.12	(35)%
Diluted Earnings per share (Rs.)	36.21	56.20	(35)%

Ipca is a backward integrated, fast growing pharmaceutical major, with a strong thrust on exports. Exports to nearly 110 countries, now account for nearly 53% of Company's income.

Premchand Godha
Chairman & Managing Director

Encl: Audited Financial Results

Ipca received Best Patent Award during the year 2007 - 08 (January 30, 2009)

We are pleased to inform that Indian Drug Manufacturers Association (IDMA) has awarded Ipca best patent award during the year 2007 - 08.

Details of our patent/s granted in the last 12 months period, 1-4-2007 to 31-3-2008. were sent to them. An expert panel has examined and evaluated applications and recommended their selection for the award.

Ipca has received IDMA Best Patent Award for our patent on Balsalazide (IN210968).

The patent has 17 claims covering various aspects of process for making Balsalazide and its disodium dihydrate salt. The main features of this improved process involve the use of readily available, cheaper and safe to use raw materials.

Financial Results (January 22, 2009)

Highlights

Q3 Income up 14% (YoY).
Q3 Profit before Forex (Loss)/ gain and Tax up 32% (YoY).
Nine months Income up 19% (YoY).
Nine months Profit before Forex (Loss)/ gain and Tax up by 50% (YoY).
2^nd Interim Dividend of 30% declared.

Q3 FINANCIAL RESULTS

The net total income for the 3^rd quarter has gone up by 14% to Rs. 313.31 crores as against Rs. 273.64 crores in the same period of previous financial year. Export Sales have increased by 20% to Rs. 169.74 crores. Net Total Income upto 31^st December, 2008 has gone up by 19% to Rs. 955.79 crores as against Rs. 806.45 crores for the same period previous year.

The profit before foreign exchange translation (loss)/gain and provision for taxes for the 3^rd quarter is up by 32% to Rs. 49.72 crores as against Rs. 37.72 crores in the same quarter previous year.

After providing for foreign exchange translation loss of Rs. 19.23 crores (Q3 previous year - foreign exchange translation gain of Rs. 10.77 crores) and for taxes, the Net Profit for the quarter is Rs. 23.18 crores as against profit of Rs. 38.34 crores in the same quarter of previous year.

The Board has declared 2^ndinterim dividend of 30% (Rs. 3/- per share) for the financial year 2008-09. This is in addition to 1^stinterim dividend of 40% (Rs. 4/- per share) already paid in the month of October, 2008.

3^rd Quarter at a glance

(Rs. Crores)

3^rd Quarter ended	31.12.2008	31.12.2007	Growth
Net Total Income	313.31	273.64	14%
Export Income	169.74	141.43	20%
Profit before forex (loss)/gain and tax	49.72	37.72	32%
Forex (loss) / gain	(19.23)	10.77	-
Net Profit after forex (loss)/gain and tax	23.18	38.34	-40%
Diluted Earnings per share (Rs.)	9.21	15.23	-40%

9 months at a glance

(Rs. Crores)

Nine months ended	31.12.2008	31.12.2007	Growth
Net Total Income	955.79	806.45	19%
Export Income	487.47	388.91	25%
Profit before forex (loss)/gain and tax	164.00	109.23	50%
Forex (loss)/gain	(60.33)	42.90	-
Net Profit	83.32	118.48	-30%
Diluted Earnings per share (Rs.)	33.10	47.07	-30%

Ipca is a backward integrated, fast growing pharmaceutical major, with a strong thrust on exports. Exports to nearly 110 countries, now account for nearly half of Company's income.

Premchand Godha
Chairman & Managing Director

Encl: Unaudited Financial Results

Media Room

Latest @ Ipca

Press Release